About Us

print version

The main goal of AngioTox is to comprehensively describe toxicity patterns and mechanisms, following treatment with the two main class of angiogenesis inhibitor, namely monoclonal antibodies (mABs) and tyrosine kinase inhibitors (TKIs). There is an urgent need to identify long term risks and to understand toxicologic mechanisms following exposure to angiogenesis inhibitors both for clinically approved and emerging agents. The AngioTox consortium brings together a unique grouping of basic, clinical and industry based scientists to achieve this objective. An in vivo modelling and digital histopathology approach will be engaged to comprehensively describe a new AngioTox Safety Panel of toxicologic markers for the clinically approved angiogenesis inhibitors bevacizumab, sorafenib and sunitinib.

There are 3 workpackages in the AngioTox Study:

Workpackage 1 - Angiogenesis Inhibitor Safety Studies in Tumour-Bearing Animal Models:

We will comprehensively assess toxicologic patterns associated with angiogenesis inhibitor treatment in animal models, either alone or in combination with a standard chemotherapeutic, as per current clinical protocols

Workpackage 2 - Histopathologic Assessment of Tissues Following Treatment with Angiogenesis Inhibitors:

The aim of this workpackage is to create digital slides of all tissues collected in work package 1, as well as from tissues obtained from relevant clinical trial studies, for online pathological analysis and to develop highly specific automated image analysis algorithms to fast-track angiogenesis inhibitor toxicologic assessment in the future. In addition, tissue microarrays (TMAs) will be prepared from each tissue for subsequent use in biomarker studies.

Workpackage 3 - Investigation of Toxicologic Mechanisms Following Angiogenesis Inhibitor Treatment:

The principal objective of this work package is to explore the biological impact of angiogenesis inhibitor treatment at the systemic and local tissue level in relation to toxicity, with the central hypothesis that angiogenesis inhibitor treatment induced toxicity is caused by interference with normal physiological homeostasis at the tissue level. We will further attempt to identify a novel biomarker of bevacizumab- and antiangiogenic tyrosine kinase inhibitor-related toxicities in pre-clinical and clinical serum samples.